Small Cap Feast
Small Cap Feast – 8th November 2016
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
Impact Holdings has delisted from AIM
Impact Holdings has delisted from AIM
What’s Cooking in the IPO Kitchen?
Diversified Gas & Oil—The US based gas and oil producer is seeking a December AIM listing to raise circa $60m
FreeAgent—Schedule one now out from the provider of accounting software to small businesses. Date and quantum of raise still to be disclosed.
Civitas Social Housing –Intention to float on Main Market from the first REIT to be listed on the London Stock Exchange offering pure play exposure to social housing
Venn Life Sciences* (VENN.L) 23.38p £14.08m
The growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has signed a new contract worth €2.5m with Sedana Medical AB. Venn will carry out a randomised, controlled, open label Phase III study to confirm efficacy and safety of sedation with isoflurane in ventilated ICU patients. This trial is confined to patients in Germany and commences immediately. The shares are on 7.8x our FYDecE earnings.
Fitbug Holdings* (FITB.L) 0.22p £23.65m
The technology developer and digital wellness pioneer announced that Heidi Steiger, has joined the Board as a Non-Executive Director with immediate effect and that Richard Goodlad has joined the board as full time Finance Director. Most recently Heidi was Eastern Region President of the Private Client Reserve of US Bank, the 5th largest commercial bank in the US. Prior to joining Fitbug Richard had been CFO of Servebase Group & then COO of Miura Systems, which he built from a virtual start-up, into a major global supplier with turnover exceeding $33m in two years.
Concepta (CPT.L) 17.75p £19.46m
The UK healthcare company targeting the personalised mobile health market with a primary focus on women’s fertility, has signed a 10 year lease for its new manufacturing facility in Doncaster, Yorkshire. The addition of this new facility will provide the Company with the necessary capacity and economies of scale as it pushes ahead with the launch of its MyLotus product for unexplained infertility into China in Q4 2016 and, following CE marking, into the UK and Europe in 2017. FY2017E revenues of £2.7m and a £1.74m pre-tax loss.
First Derivatives (FDP.L) 2,004p £495m
First Derivatives has announced its entry into the retail analytics market, using its Kx technology as a platform to develop solutions under a team of leading retail technology specialists recently recruited by the Group. The move opens up an addressable opportunity which, according to MarketsandMarkets, is expected to grow at 19% per annum to be valued at more than $5 billion per annum in 2020. FYFeb17E £140m revs and £17.87m PBT. 37.1xPE and 0.9% yield.
San Leon Energy (SLE.L) 41.75p £184.96m
Avobone and San Leon Energy have settled a number of ongoing disputes in respect of various matters including a final award in an ICC arbitration dated 21 May 2015. The total settlement of €23.3 million plus interest to be paid to Avobone by San Leon will be paid in instalment to complete by the end of 2017. The provision made in the 2015 audited accounts for the Avobone dispute was approximately €20.6 million. The difference is due to interest, exchange rate fluctuations, and further legal costs. SLE still expects to distribute 50% of free cash flow from OML18.
Telit Communications (TCM.L) 249.75p £288.84m
FYDec16 trading update from the enabler of the Internet of Things. The Group has increased its adjusted EBITDA and earnings per share guidance towards the middle and upper end of the previous range, as a result of better gross margin and operational cost discipline. The Group has also narrowed the revenue guidance range. Guidance: Revenue $360-$375m, Adjusted EBITDA $54-59m. EPS 26-30c.
Grafenia (GRA.L) 8.75p £3.97m
H1Sep16 results from the provider of systems to the graphic arts industry. Revenue down 2.65% to £5.14m with higher volumes and lower pricing. EBITDA was £0.46m (2015: £0.59m), a decline of 22.03%. There was an operating loss of £0.42m(2015: operating loss £0.18m). Cash up to £0.5m from £0.34m. Remains cautious for H2. If transactional print revenues continue to perform below internal budgets, it is likely that full year results will be significantly below market expectations.
Paysafe Group (PAYS.L) 430.2p £2.1bn
Trading update from global provider of payment solutions. Further to the update on trading given at the Group’s Half-Year results in August, Paysafe continues to perform in line with previously upgraded management expectations. The Group’s expectations for revenue and adjusted EBITDA remain unchanged, with revenue in the range of $970m – $990m and an adjusted EBITDA range of $287m – $293m, based on an adjusted EBITDA margin of 29.6%. 13.7x FYDec16E PE.
Tyman (TYMN.L) 264p £470m
Trading update for the period from 30 June 2016 to date from the international supplier of engineered components to the door and window industry. 2016 Trading remains in line. Encouraging growth has continued in European markets and volumes have held up in UK and Irish markets, offsetting slower trading in North America since the half year. Broad international exposure and balanced portfolio means Tyman is well positioned for 2017 and beyond, despite macroeconomic uncertainties and continued currency volatility. FYDec16E rev £445.7m. 21.52EPS
Savannah resources (SAV.L) 4.37p £19.66m
Initial resource estimation over two of the four deposits currently defined at the Mutamba project in Mozambique. 10% stake with earn in up to 51% under Rio Tinto Consortium. Initial Indicated and Inferred Mineral Resource Estimate of 3.5bn tonnes at 3.8% Total Heavy Minerals. Mineral Resource Estimate contains 81 million tonnes (“Mt”) of ilmenite, 2.2Mt rutile and 3.8Mt zircon. 52% Indicated and 48% Inferred. Resource estimation in respect of the Ravene and Chilubane deposits still to be completed.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.